Administrative
Core
Nonhuman Primate Core
Computational Biology Core
Small Animal Core
BSL4 Core
Pathogenesis Expression Core
Law,
Policy and Ethics
Trans-Center Cores
National Small Molecule Screening Laboratory
RCE
Communications
Nonhuman Primate Aerobiology
Core
Passive
immunotherapeutics for Select Agents
|
BSL4 Core
Institution: University
of Texas Medical Branch (UTMB) at Galveston, Galveston, TX
Director: C.
J. Peters, M.D.
Shope BSL4 Laboratory
Director: Michael R. Holbrook, Ph.D. – UTMB,
Galveston, TX
Associate Director: Jean Patterson, Ph.D. – Southwest Foundation
for Biomedical Research (SFBR), San Antonio, TX
BSL4 Laboratory Scientific Manager: Ricardo
Carrion, Jr., Ph.D. – SFBR,
San Antonio, TX Description: The WRCE BSL4 Core provides the infrastructure to
permit safe work to be performed on aerosol-infectious, potentially
lethal agents. The Core consists of the mechanical safeguards of
two high-containment laboratories, the provision of training in
BSL4 operations, and assistance in operations within the laboratories.
Part of this core is located at the Southwest Foundation for Biomedical
Research (SFBR) in San Antonio, Texas, where 1200 square feet of
BSL4 laboratory space is available. The other component provides
2000 square feet at the University of Texas Medical Branch (UTMB)
in Galveston, Texas. The SFBR facility has been in operation since
March of 2000 and provides space for microbiological operations
as well as housing for rodents and small nonhuman primates. The
UTMB facility, named the Robert E. Shope, M.D. Laboratory, has
been in operation since June of 2004, and includes space for animals.
Both facilities have access to a high intensity gamma irradiator
allowing inactivation of samples for further analysis outside the
BSL4 laboratory. This core is essential for work on the hemorrhagic
fever viruses and multi-drug resistant bacteria. Generally, investigators
are trained in BSL4 containment and work within the BSL4 laboratory
on their own projects, but technical assistance is available. Approximately
20% of the activity is devoted to challenge experiments using established
animal models to test newly developed vaccines and therapeutics.
|